Dexcom (DXCM) Cost of Revenue (2010 - 2026)

Dexcom (DXCM) has 17 years of Cost of Revenue data on file, last reported at $441.6 million in Q1 2026.

• Quarterly Cost of Revenue fell 1.21% year-over-year to $441.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 10.22% YoY) and the FY2025 annual result came in at $1.9 billion, up 16.64% from the prior year.
• Cost of Revenue declined to $441.6 million in Q1 2026 per DXCM's latest filing, from $466.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $477.9 million in Q3 2025 and bottomed at $230.7 million in Q1 2022.
• The 5-year median for Cost of Revenue is $377.6 million (2024), against an average of $368.0 million.
• The widest annual swing landed in 2022, when Cost of Revenue soared 43.2%; it then slipped 1.21% in 2026.
• Tracing DXCM's Cost of Revenue over 5 years: stood at $273.9 million in 2022, then jumped by 37.97% to $377.9 million in 2023, then advanced by 21.12% to $457.7 million in 2024, then advanced by 2.01% to $466.9 million in 2025, then dropped by 5.42% to $441.6 million in 2026.
• Per Business Quant, the three latest DXCM Cost of Revenue figures stand at $441.6 million (Q1 2026), $466.9 million (Q4 2025), and $477.9 million (Q3 2025).

Peer Comparison